NCT06207123 2026-03-18
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
Phase 1/2 Recruiting
Clinical Trials
91 trialsNCT07479979 2026-03-18
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
NCT06930651 2026-03-11
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT05434689 2026-03-05
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT05789589 2026-03-04
ADORATION
Baptist Health South Florida
Phase 1/2 Recruiting
NCT06232044 2026-03-04
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Suspended
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT00378105 2026-02-24
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT01297764 2026-02-19
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT05199311 2026-02-18
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
Phase 1/2 Recruiting
NCT04822337 2026-01-20
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05848687 2026-01-13
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT03808610 2026-01-09
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06383572 2025-12-23
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT02553460 2025-12-10
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT06645678 2025-12-03
MELT-MM
Seoul National University Hospital
Phase 1/2 Recruiting
NCT05392946 2025-10-29
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Phase 1/2 Active not recruiting
NCT06785415 2025-09-30
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Recruiting
NCT05192889 2025-09-22
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT05658640 2025-09-16
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05745714 2025-09-16
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05751044 2025-09-16
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT05451771 2025-07-08
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Phase 1/2 Recruiting
NCT03817320 2025-06-17
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Active not recruiting
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04947189 2025-05-15
4CAST
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05289908 2025-05-04
Intrathecal Pemetrexed for Leptomeningeal Metastasis
The First Hospital of Jilin University
Phase 1/2 Completed
NCT04896658 2025-04-03
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT03773107 2025-01-13
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Completed
NCT02002598 2024-09-19
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
Phase 1/2 Terminated
NCT02542657 2024-09-19
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
University of California, Davis
Phase 1/2 Active not recruiting
NCT02633059 2024-09-19
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT05422027 2024-06-17
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06376721 2024-04-19
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 1/2 Recruiting
NCT02119468 2024-03-15
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT05432934 2023-12-07
TAP-DEX
University of Saskatchewan
Phase 1/2 Unknown
NCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting
NCT03201250 2023-09-08
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
University of Nebraska
Phase 1/2 Terminated
NCT03705507 2023-05-11
SeluDex
University of Birmingham
Phase 1/2 Terminated
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT02186834 2023-01-04
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT05581875 2022-10-17
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
Phase 1/2 Not yet recruiting